343 related articles for article (PubMed ID: 34057243)
21. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Ebinger JE; Fert-Bober J; Printsev I; Wu M; Sun N; Prostko JC; Frias EC; Stewart JL; Van Eyk JE; Braun JG; Cheng S; Sobhani K
Nat Med; 2021 Jun; 27(6):981-984. PubMed ID: 33795870
[TBL] [Abstract][Full Text] [Related]
22. The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
Marchesi F; Pimpinelli F; Sperandio E; Papa E; Falcucci P; Pontone M; di Martino S; de Latouliere L; Orlandi G; Morrone A; Ciliberto G; Mengarelli A;
Br J Haematol; 2022 Jan; 196(2):362-367. PubMed ID: 34490627
[No Abstract] [Full Text] [Related]
23. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
24. Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.
Malard F; Gaugler B; Gozlan J; Bouquet L; Fofana D; Siblany L; Eshagh D; Adotevi O; Laheurte C; Ricard L; Dulery R; Stocker N; van de Wyngaert Z; Genthon A; Banet A; Memoli M; Ikhlef S; Sestilli S; Vekhof A; Brissot E; Marjanovic Z; Chantran Y; Cuervo N; Ballot E; Morand-Joubert L; Mohty M
Blood Cancer J; 2021 Aug; 11(8):142. PubMed ID: 34376633
[TBL] [Abstract][Full Text] [Related]
25. Evolving threat.
Kupferschmidt K
Science; 2021 Aug; 373(6557):844-849. PubMed ID: 34413220
[No Abstract] [Full Text] [Related]
26. Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines-Correlates of Immunogenicity Parameters with Protection.
Vajo Z
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215791
[TBL] [Abstract][Full Text] [Related]
27. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Golding B; Lee Y; Golding H; Khurana S
Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
[No Abstract] [Full Text] [Related]
28. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
29. [Immune memory against SARS-CoV-2: Antibodies against the initial infection and memory B cells for the future ones].
Reynaud CA; Weill JC; Chappert P; Mahévas M
Med Sci (Paris); 2021; 37(8-9):722-725. PubMed ID: 34346865
[No Abstract] [Full Text] [Related]
30. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
Mittal A; Khattri A; Verma V
PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
[TBL] [Abstract][Full Text] [Related]
31. Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants.
Takagi A; Matsui M
Microbiol Spectr; 2021 Dec; 9(3):e0165921. PubMed ID: 34937174
[TBL] [Abstract][Full Text] [Related]
32. Viral Proteins under 70 Kilodaltons in Size Prevent the Development of Long-Lasting B-Cell Immune Memory and IgG2a Prevention in COVID-19 Vaccines.
Martín Oncina J
Crit Rev Immunol; 2020; 40(6):465-473. PubMed ID: 33900691
[TBL] [Abstract][Full Text] [Related]
33. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity.
Hagin D; Freund T; Navon M; Halperin T; Adir D; Marom R; Levi I; Benor S; Alcalay Y; Freund NT
J Allergy Clin Immunol; 2021 Sep; 148(3):739-749. PubMed ID: 34087242
[TBL] [Abstract][Full Text] [Related]
35. Omicron likely to weaken COVID vaccine protection.
Callaway E
Nature; 2021 Dec; 600(7889):367-368. PubMed ID: 34880488
[No Abstract] [Full Text] [Related]
36. Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.
Liebers N; Speer C; Benning L; Bruch PM; Kraemer I; Meissner J; Schnitzler P; Kräusslich HG; Dreger P; Mueller-Tidow C; Poschke I; Dietrich S
Blood; 2022 Jan; 139(1):142-147. PubMed ID: 34669919
[No Abstract] [Full Text] [Related]
37. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.
Messali S; Bertelli A; Campisi G; Zani A; Ciccozzi M; Caruso A; Caccuri F
J Med Virol; 2021 Dec; 93(12):6468-6470. PubMed ID: 34329486
[No Abstract] [Full Text] [Related]
38. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
Front Immunol; 2021; 12():795741. PubMed ID: 34925381
[TBL] [Abstract][Full Text] [Related]
39. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
Front Immunol; 2021; 12():737083. PubMed ID: 34539673
[TBL] [Abstract][Full Text] [Related]
40. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.
Kozlovskaya LI; Piniaeva AN; Ignatyev GM; Gordeychuk IV; Volok VP; Rogova YV; Shishova AA; Kovpak AA; Ivin YY; Antonova LP; Mefyod KM; Prokosheva LS; Sibirkina AS; Tarasova YY; Bayurova EO; Gancharova OS; Illarionova VV; Glukhov GS; Sokolova OS; Shaitan KV; Moysenovich AM; Gulyaev SA; Gulyaeva TV; Moroz AV; Gmyl LV; Ipatova EG; Kirpichnikov MP; Egorov AM; Siniugina AA; Ishmukhametov AA
Emerg Microbes Infect; 2021 Dec; 10(1):1790-1806. PubMed ID: 34427172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]